InvestorsHub Logo
Followers 0
Posts 4
Boards Moderated 0
Alias Born 01/17/2022

Re: None

Monday, 01/17/2022 7:22:31 PM

Monday, January 17, 2022 7:22:31 PM

Post# of 3533
Rockley, Dexcom, Abbott Labs Blah, Blah, Blah, Blah.

I have been reading this message board for some time and thought it was time to provide another opinion.

Rockley this and Rockley that... Rockley has technology similar to DiaMonTech. DiaMonTech's Mean Absolute Relative Difference is 11.3% to 12.1%. Compare to Know Labs 6.7% or less. Will Rockley get FDA approval as a medical device??? Looks like its application may be limited to fitness devices.

Dexcom's CEO touted the performance of its new next generation G7 CGM. (See Post 3229). The G7 has a MARD of 8.1% to 8.2%. Dexcom's CEO would really have something to brag about if he had Know Labs Technology. Noninvasive, More accurate and Much Cheaper.

Abbott Labs. Same story. Abbott Freestyle Libre 2 has a MARD of 9.0% to 9.3%. Again Know Labs is less invasive, more accurate and cheaper.

The difference I see between Know Labs technology and the competition is that Know Labs is a platform that also can identify over 100 analytes with the same accuracy including but not limited to alcohol, drug concentrations, hormonal levels, C Reactive Protein, white Blood Cells and the list goes on. Looking solely at C Reactive Protein is significant in and of itself. C Reactive protein levels are diagnostic of chronic inflammatory diseases, heart attack, infections and certain cancers. Further, these levels can be tracked over time.

In my view, Know Labs has a once in a life time technology that will transform medical diagnostics and/or all monitors. GLTA
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KNW News